Sentences with phrase «on immunotherapies»

So far this year, American Veterinarian ® has reported on immunotherapies that may slow growth or even shrink gliomas in dogs and humans, a liquid biopsy assessment tool to detect tumor cell mutation, and a shared study between the American Kennel Club Canine Health Foundation and the V Foundation for Cancer Research on the treatment of bladder cancer.

The Gynecologic Oncology Group study is sponsored by vaccine developers, Advaxis, Inc., a Princeton, New Jersey - based company that focuses on immunotherapies to combat cancer.

For a number of years, Wolchok had been conducting research on immunotherapies for patients with metastatic melanoma.

Roughly 10 percent of melanoma patients on immunotherapies, for instance, experience this phenomenon.

Part of the problem may be that NewLink is a small company, with about 100 employees, that has concentrated on immunotherapies to fight cancer in recent years.

So Swanton is focusing on immunotherapies — strategies that help the immune system to recognize and destroy cancer cells.

But while thousands of clinical trials on immunotherapy drugs, of which many are predicted to fail, are springing up, the depth of information on neoantigen vaccines is much shallower: Just two studies on neoantigen vaccines for melanoma, recently profiled in Nature, were completed last year in Boston and Germany.

This increased survival rate places a high value on immunotherapy drugs and the companies that research and produce them.

BioMed Valley Discoveries in Kansas City is one of those pharmaceutical companies hot on the immunotherapy trail.

Now, pharmaceutical manufacturers are jostling for position on the immunotherapy wave, with BMS holding the leader's position.

Allison, chair of the immunology department at the University of Texas M.D. Anderson Cancer Center in Houston and executive director of its research center on immunotherapy, spoke with Scientific American about the future prospects and limitations of immunotherapy.

Dr. Jennifer S. Temel, clinical director of thoracic oncology at Massachusetts General Hospital, alluded to the emerging research on immunotherapy in a presentation to palliative care and hospice clinicians in February.

That's also what Kato and his colleagues were hoping, as their patients» cancer appeared to grow in their first weeks on immunotherapy.

Much of the research to be presented is focused on immunotherapy, which is seen as the most promising advance in cancer treatment in decades.

The company's proprietary cell therapy programs are based on its immunotherapy and pluripotent stem cell platform technologies.

For this reason, my Roswell Park colleague Dr. Marc Ernstoff and I have been helping to create guidance for medical professionals who care for patients on immunotherapy — an effort mentioned in a recent Washington Post article.

In those rare cases where patients on immunotherapy experience adverse symptoms, it's extremely important for them to communicate what they're experiencing to their care teams and seek appropriate medical attention quickly.

At RPCI, he maintains an active research program focused on finding new and efficacious therapies for cancer based on immunotherapy and gene therapy, overseeing many scientists in his research lab.

This on - demand webinar offers advice from three experts on immunotherapy in non-small cell lung cancer.

2nd International Conference on Immunotherapy in Pediatric Oncology, Oct.11 - 12, 2010 Houston / TX, USA.

«At City of Hope we have great scientists working on immunotherapy,» said Rosenthal.

The company's focus on immunotherapy is what originally attracted me to iTeos Therapeutics.

Allergen - specific immunotherapy makes dogs less sensitive to their allergens and 60 - 80 % of patients improve on immunotherapy.

Not exact matches

More news on the GBM front: Tomorrow (Thursday) and Friday, the Parker Institute for Cancer Immunotherapy, is hosting a glioblastoma immuno - oncology research summit in Los Angeles — bringing together top industry and academic scientists to share their research.

With a critical mass of 450,000 patients annually among them, the six centers have agreed to combine their efforts on planning clinical trials in immunotherapy, recruit patients quickly, and share the information learned — which could be the single biggest factor in speeding up drug development.

In mid-April — in an over-the-top, celebrity - gawking, Lady Gaga — serenading event that brought 900 people in black tie to his 2 1/2 - acre backyard in L.A.'s Holmby Hills neighborhood — Parker announced a $ 250 million cancer research hack that he'd been working on quietly, diligently, for three years: the Parker Institute for Cancer Immunotherapy.

«It also brings in the question of diet,» says Wargo, who is now working on new clinical studies on the microbiome with the Parker Institute for Cancer Immunotherapy.

HOUSTON, April 20, 2018 (GLOBE NEWSWIRE)-- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the closing of its previously announced underwritten public offering of 9,200,000 shares of its common stock, including 1,200,000 shares sold pursuant to the underwriters» full exercise of their option to purchase additional shares, at a public offering price of $ 7.50 per share.

On Thursday, Bristol - Myers Squibb abruptly ditched an accelerated approval application for a combo of its rival immunotherapy Opdivo and an older drug called Yervoy.

Immunotherapy is praised by researchers because it is targeted, focusing on cancerous cells rather than healthy tissue, as well as potentially durable.

The 36 - year - old Silicon Valley billionaire, who co-founded the music - sharing website Napster when he was 19, announced the creation of the Parker Institute for Cancer Immunotherapy on Wednesday via his philanthropic foundation — the Parker Foundation.

The Parker Institute for Cancer Immunotherapy will focus on the emerging field of cancer immunotherapy, which harnesses the body's immune system to fight Immunotherapy will focus on the emerging field of cancer immunotherapy, which harnesses the body's immune system to fight immunotherapy, which harnesses the body's immune system to fight cancer cells.

HOUSTON, April 17, 2018 (GLOBE NEWSWIRE)-- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM), a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders, today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $ 7.50 per share.

The institute, which includes over 40 laboratories and more than 300 researchers, said the research would focus on modifying a patient's own immune system T - cells to target a tumor, studying ways to boost patient response to current immunotherapy drugs.

HOUSTON, April 16, 2018 (GLOBE NEWSWIRE)-- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM), a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that it has commenced an underwritten public offering of 7,000,000 shares of its common stock.

Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders.

As we explained in our ASCO primer, pharma giants like Merck (mrk) and Bristol - Myers Squibb (bmy) and biotechs like Juno (juno) and Kite Pharma (kite) had a lot to prove through their clinical trial updates on experimental immunotherapies.

Fortune spoke with Brad Loncar, an independent biotech investor who launched the first - ever cancer immunotherapy index fund last year, about the biggest winners out of ASCO and which cancer drug hopefuls you should keep an eye on going forward.

Merck and Bristol - Myers Squibb each have approved immunotherapy drugs, while Gilead Sciences announced Monday it plans to acquire Kite Pharma for $ 11.9 billion, just a few months before the FDA is expected to approve Kite's CAR - T drug for lymphoma on Nov. 29.

The Napster founder and former Facebook president created the Parker Institute for Cancer Immunotherapy, which will focus on using the body's immune system to combat cancer cells.

Analysts have said that the company could make for a good acquisition, but more data on its cancer immunotherapy drugs may need to come in first.

She sits on the Board of Trustees of the Parker Institute for Cancer Immunotherapy and on the corporate board of directors of the Waters Corporation and GlaxoSmithKline plc..

So, Loncar took matters into his own hands and created a new type of biotech index that focuses exclusively on the red - hot field of cancer immunotherapy drugs (treatments which use the body's immune system as a conduit to fight cancer).

Loncar's fund, the Loncar Cancer Immunotherapy ETF, trades on the NASDAQ under the ticker CNCR and launched last fall.

It's a type of cancer immunotherapy, which harnesses the body's immune system to take on cancer cells.

Brad Loncar, CEO of Loncar Investments, weighs in on recent developments in the scramble to develop CAR T cancer immunotherapies.

The Kamens claim the main thing that distinguishes their foundation from other brain tumor foundations is their focus on pediatric brain cancer specifically, as well as their close ties with pharmaceutical and biotech companies working in the fields of immunotherapy and target gene therapy.

He has served on National Cancer Institute (NCI) Steering Committees for Genitourinary Cancer (GUSC) and Investigational Drugs (IDSC)- Immunotherapy Task Force, and is a senior editor for Cancer Immunology Research.

(Reuters)- Gilead Sciences Inc agreed to buy Kite Pharma Inc in a nearly $ 12 billion deal on Monday, as it looks to replace flagging sales from hepatitis C drugs with an emerging and expensive class of cancer immunotherapies that are expected to generate billions of dollars in revenue.

The reason why I think Merck is the safest way to invest in immunotherapy is because the company has a diverse portfolio of FDA approved drugs on the market.